In the Breaking News session, Prof. Axel Merseburger (University Hospital Schleswig-Holstein, Germany) announced the first results from SAUL, a phase 3b study evaluating the safety of atezolizumab in 997 patients with locally advanced or metastatic urothelial carcinoma (mUC) including several clinically relevant populations reflective of real-world clinical practice. Data from the study showed that both safety and efficacy, a secondary endpoint, were consistent with previous studies in both the overall population and a subgroup of patients corresponding to the patient population of the pivotal phase 3 study IMvigor211 (“IMvigor211-like”) .
SAUL is the largest prospective safety study of a cancer immunotherapy in mUC and provides information about atezolizumab in a real-world setting. This open label, single-arm, multicentre study was designed to assess the safety of atezolizumab as a second- to fourth-line treatment for people with locally advanced or m...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« HPV and Penile Cancer Next Article
Extrapolating Data from Clinical Trials as We Treat Patients in Real Life »
Table of Contents: EAU 2019
Renal Transplantation and Renal Cell Carcinoma
Lower Urinary Tract Symptoms
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.